ACC.19: 3 Studies in Cardioprotection

Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.

Source: ConsultantLive - March 25, 2019 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: Cardiovascular Disease Source Type: news